Nanjing Leads Biolabs (HKG:9887) orally presented updated data from a phase II study of its LBL-024 at the 2026 World Conference on Lung Cancer.
The trial tested the drug in combination with chemotherapy as first-line treatment for patients with non-small cell lung cancer, according to a Monday bourse disclosure.
The updated data demonstrated high response rates, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.